227 related articles for article (PubMed ID: 27322816)
21. Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with MLL gene rearrangements: A report from the Japan Infant Leukemia Study Group.
Tomizawa D; Koh K; Hirayama M; Miyamura T; Hatanaka M; Saikawa Y; Ishii E
Pediatr Blood Cancer; 2009 Jul; 52(7):808-13. PubMed ID: 19229974
[TBL] [Abstract][Full Text] [Related]
22. MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: a Children's Oncology Group Study.
Matlawska-Wasowska K; Kang H; Devidas M; Wen J; Harvey RC; Nickl CK; Ness SA; Rusch M; Li Y; Onozawa M; Martinez C; Wood BL; Asselin BL; Chen IM; Roberts KG; Baruchel A; Soulier J; Dombret H; Zhang J; Larson RS; Raetz EA; Carroll WL; Winick NJ; Aplan PD; Loh ML; Mullighan CG; Hunger SP; Heerema NA; Carroll AJ; Dunsmore KP; Winter SS
Leukemia; 2016 Sep; 30(9):1909-12. PubMed ID: 26952838
[No Abstract] [Full Text] [Related]
23. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents.
Furuichi Y; Goi K; Inukai T; Sato H; Nemoto A; Takahashi K; Akahane K; Hirose K; Honna H; Kuroda I; Zhang X; Kagami K; Hayashi Y; Harigaya K; Nakazawa S; Sugita K
Cancer Res; 2007 Oct; 67(20):9852-61. PubMed ID: 17942916
[TBL] [Abstract][Full Text] [Related]
24. Relatively favorable prognosis for MLL-rearranged childhood acute leukemia with reciprocal translocations.
Yang L; Ding L; Liang J; Chen J; Tang Y; Xue H; Gu L; Shen S; Li B; Chen J
Pediatr Blood Cancer; 2018 Oct; 65(10):e27266. PubMed ID: 29943896
[TBL] [Abstract][Full Text] [Related]
25. Identification and characterization of relapse-initiating cells in MLL-rearranged infant ALL by single-cell transcriptomics.
Candelli T; Schneider P; Garrido Castro P; Jones LA; Bodewes E; Rockx-Brouwer D; Pieters R; Holstege FCP; Margaritis T; Stam RW
Leukemia; 2022 Jan; 36(1):58-67. PubMed ID: 34304246
[TBL] [Abstract][Full Text] [Related]
26. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias.
Andersson AK; Ma J; Wang J; Chen X; Gedman AL; Dang J; Nakitandwe J; Holmfeldt L; Parker M; Easton J; Huether R; Kriwacki R; Rusch M; Wu G; Li Y; Mulder H; Raimondi S; Pounds S; Kang G; Shi L; Becksfort J; Gupta P; Payne-Turner D; Vadodaria B; Boggs K; Yergeau D; Manne J; Song G; Edmonson M; Nagahawatte P; Wei L; Cheng C; Pei D; Sutton R; Venn NC; Chetcuti A; Rush A; Catchpoole D; Heldrup J; Fioretos T; Lu C; Ding L; Pui CH; Shurtleff S; Mullighan CG; Mardis ER; Wilson RK; Gruber TA; Zhang J; Downing JR;
Nat Genet; 2015 Apr; 47(4):330-7. PubMed ID: 25730765
[TBL] [Abstract][Full Text] [Related]
27. Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale.
Stumpel DJ; Schotte D; Lange-Turenhout EA; Schneider P; Seslija L; de Menezes RX; Marquez VE; Pieters R; den Boer ML; Stam RW
Leukemia; 2011 Mar; 25(3):429-39. PubMed ID: 21116279
[TBL] [Abstract][Full Text] [Related]
28. Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in
Fournier E; Inchiappa L; Delattre C; Pignon JM; Danicourt F; Bemba M; Roche-Lestienne C; Daudignon A; Decool G; Roumier C; Dumezy F; Fournier L; Grardel N; Preudhomme C; Duployez N
Leuk Lymphoma; 2019 Jul; 60(7):1827-1830. PubMed ID: 30616415
[No Abstract] [Full Text] [Related]
29. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.
Stam RW; den Boer ML; Passier MM; Janka-Schaub GE; Sallan SE; Armstrong SA; Pieters R
Leukemia; 2006 Feb; 20(2):264-71. PubMed ID: 16357833
[TBL] [Abstract][Full Text] [Related]
30. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Stam RW; Den Boer ML; Schneider P; de Boer J; Hagelstein J; Valsecchi MG; de Lorenzo P; Sallan SE; Brady HJ; Armstrong SA; Pieters R
Blood; 2010 Feb; 115(5):1018-25. PubMed ID: 19965632
[TBL] [Abstract][Full Text] [Related]
31. Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in
Wölfl M; Rasche M; Eyrich M; Schmid R; Reinhardt D; Schlegel PG
Blood Adv; 2018 Jun; 2(12):1382-1385. PubMed ID: 29898879
[TBL] [Abstract][Full Text] [Related]
32. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Spijkers-Hagelstein JA; Mimoso Pinhanços S; Schneider P; Pieters R; Stam RW
Leukemia; 2013 Apr; 27(5):1063-71. PubMed ID: 23334362
[TBL] [Abstract][Full Text] [Related]
33. KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease.
Forgione MO; McClure BJ; Eadie LN; Yeung DT; White DL
Cancer Lett; 2020 Jan; 469():410-418. PubMed ID: 31705930
[TBL] [Abstract][Full Text] [Related]
34. MLL-Rearranged Acute Lymphoblastic Leukemia.
El Chaer F; Keng M; Ballen KK
Curr Hematol Malig Rep; 2020 Apr; 15(2):83-89. PubMed ID: 32350732
[TBL] [Abstract][Full Text] [Related]
35. Romidepsin enhances the efficacy of cytarabine
Cheung LC; Cruickshank MN; Hughes AM; Singh S; Chua GA; Ford J; Ferrari E; Oommen J; Malinge S; Lock RB; Kees UR; Kotecha RS
Haematologica; 2019 Jul; 104(7):e300-e303. PubMed ID: 30679330
[No Abstract] [Full Text] [Related]
36. B-cell lymphoblastic lymphoma with cutaneous involvement and a KMT2A gene rearrangement.
Kemps PG; Cleven AHG; van Wezel T; van Eijk R; Bot FJ; Veelken H; van Balen P; Kerkhoffs JH
Am J Hematol; 2020 Nov; 95(11):1427-1429. PubMed ID: 32243611
[No Abstract] [Full Text] [Related]
37. MLL-rearranged mixed phenotype acute leukemia masquerading as B-cell ALL.
Yang W; Tran P; Khan Z; Rezk S; O'Brien S
Leuk Lymphoma; 2017 Jun; 58(6):1498-1501. PubMed ID: 27774846
[No Abstract] [Full Text] [Related]
38. Rearrangements of ATP5L-KMT2A in acute lymphoblastic leukaemia.
Ferrari A; Ghelli Luserna Di Rora A; Domizio C; Papayannidis C; Simonetti G; Maria Hernández-Rivas J; Rondoni M; Giglio F; Abruzzese E; Imovilli A; Iacobucci I; Calistri D; Martinelli G
Br J Haematol; 2021 Mar; 192(6):e139-e144. PubMed ID: 33314053
[No Abstract] [Full Text] [Related]
39. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.
Brown P; Levis M; McIntyre E; Griesemer M; Small D
Leukemia; 2006 Aug; 20(8):1368-76. PubMed ID: 16761017
[TBL] [Abstract][Full Text] [Related]
40. A pediatric case of
Murphy L; Siegele B; Carstens B; Hartman L; Faulk K
Leuk Lymphoma; 2024 Jun; 65(6):843-847. PubMed ID: 38372299
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]